Anika Therapeutics Inc
Abierto
SectorSanidad
14.57 -0.95
Resumen
Variación precio
24h
Mínimo
14.45
Máximo
14.71
Ingresos | -5.3M -5.1M |
|---|---|
Ventas | -1M 30M |
BPA | -0.37 |
Margen de beneficios | -17.074 |
Empleados | 235 |
EBITDA | -6.3M -4.1M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +15.49% upside |
Próximas Ganancias | 29 jul 2026 |
|---|
Capitalización Mercado | -34M 194M |
|---|---|
Apertura anterior | 15.52 |
Cierre anterior | 14.57 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
146 / 342 Clasificación en Healthcare
Anika Therapeutics Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.